# MNPR catalysts: Monopar Therapeutics PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mnpr/catalysts

> Monopar Therapeutics (MNPR) has 1 upcoming catalyst. The next is the ALXN1840 NDA/BLA submission, March 31, 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MNPR?

Monopar Therapeutics (MNPR) has 1 upcoming catalyst. The next is the ALXN1840 NDA/BLA submission, March 31, 2028. Press release filed with the SEC (EX-99): "Examples of these forward-looking statements include statements concerning the following: that Dr. Kent is leading the Company's medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that the Company is on track to complete the NDA submission within the next several weeks; and that Monopar expects its current funds to support operations through at least March 31, 2028." [Calendar and source filings](https://sec-api.dev/companies/mnpr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-036385, https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex_1043550.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/mnpr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Monopar Therapeutics |
| Ticker | MNPR (Nasdaq) |
| SEC CIK | 1645469 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mnpr |

## Cash runway

Cash $105.1M as of 2026-09-30; quarterly burn $6.2M; about 51.1 months of runway at that rate (XBRL company facts, accession 0001437749-26-036384).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [MNPR-101 trial start](https://sec-api.dev/pdufa/mnpr-101) | MNPR | advanced cancers, and in April 2024, we launched the Phase 1 trial | completed | "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645469/000143774926036384/mnpr20260930_10q.htm)) |
| Apr 2024 | [MNPR-101 trial start](https://sec-api.dev/pdufa/mnpr-101) | MNPR |  | completed | "In April 2024, we launched the Phase 1 trial, and in July 2024, we announced the enrollment of our first patient." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/mnpr20251231_10k.htm)) |
| December 5, 2024 | [MNPR-101 trial start](https://sec-api.dev/pdufa/mnpr-101) | MNPR |  | completed | "On December 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that a first patient was dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm)) |
| March 31, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "WILMETTE, Ill., March 31, 2025 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/ex_795025.htm)) |
| May 13, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, May 13, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/ex_815119.htm)) |
| August 12, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, August 12, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/ex_849537.htm)) |
| November 13, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, November 13, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/ex_883774.htm)) |
| early 2026 | [MNPR-101 NDA/BLA submission](https://sec-api.dev/pdufa/mnpr-101) | MNPR |  | scheduled | "Examples of these forward-looking statements include statements concerning: that Monopar is responsible for advancing the program commercially; that Monopar is preparing to submit an NDA to the FDA in early 2026; that Monopar continues its preclinical work with MNPR-101-Ac with the plan to enter the clinic in the future; and that Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/ex_849537.htm)) |
| March 27, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, Ill., March 27, 2026 - Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/ex_937864.htm)) |
| mid-2026 | [ALXN1840 NDA/BLA submission](https://sec-api.dev/pdufa/alxn1840) | MNPR |  | scheduled | "Examples of these forward-looking statements include statements concerning: that the neurologic benefit supports ALXN1840's potential as a novel treatment option for Wilson disease; that ALXN1840 has the potential to meaningfully change the treatment landscape for Wilson disease patients with neurologic symptoms by delivering both improved clinical outcomes and a lower likelihood of neurologic deterioration compared to standard of care; that these findings support the continued advancement of ALXN1840 toward the planned submission of an NDA to the FDA in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926012751/ex_947617.htm)) |
| May 14, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, May 14, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/ex_962976.htm)) |
| August 12, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, August 12, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/ex_1003235.htm)) |
| November 12, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, November 12, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex_1043550.htm)) |
| March 31, 2028 | [ALXN1840 NDA/BLA submission](https://sec-api.dev/pdufa/alxn1840) | MNPR |  | scheduled | "Examples of these forward-looking statements include statements concerning the following: that Dr. Kent is leading the Company's medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that the Company is on track to complete the NDA submission within the next several weeks; and that Monopar expects its current funds to support operations through at least March 31, 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex_1043550.htm)) |

## Drugs

- [ALXN1840](https://sec-api.dev/pdufa/alxn1840): 
- [MNPR-101](https://sec-api.dev/pdufa/mnpr-101): advanced cancers, and in april 2024, we launched the phase 1 trial

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mnpr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MNPR catalysts: Monopar Therapeutics PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mnpr/catalysts

```bibtex
@misc{secapidev_companies_mnpr_catalysts_20261116,
  title        = {MNPR catalysts: Monopar Therapeutics PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mnpr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mnpr_catalysts_20261116","title":"MNPR catalysts: Monopar Therapeutics PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mnpr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
